Orthopedics Department, Zhongshan City People's Hospital, Zhongshan 528403, China.
Med Oncol. 2013;30(3):608. doi: 10.1007/s12032-013-0608-6. Epub 2013 May 18.
Neutral endopeptidase (NEP/CD10) and dipeptidyl peptidase IV (DPP IV/CD26) are both ubiquitous glycopeptidases which play important roles in tumor pathogenesis and development. The aim of this study was to investigate the expression patterns and the prognostic significance of CD10 and CD26 in osteosarcoma patients. CD10 and CD26 expression in 116 pairs of primary osteosarcoma and corresponding noncancerous bone tissue samples from the same specimens were detected by immunohistochemistry. The Spearman's correlation was calculated between the expression levels of CD10 and CD26 in osteosarcoma tissues. The associations of CD10 and CD26 expression with the clinicopathologic features and with the prognosis of osteosarcoma were subsequently assessed. Both CD10 expression and CD26 expression in osteosarcoma tissues were significantly higher than those in corresponding noncancerous bone tissue samples (both P < 0.001). Overexpression of CD10 and CD26 were respectively observed in 68.10 % (79/116) and 70.69 % (82/116) of osteosarcoma tissues. A significant correlation was found between CD10 expression and CD26 expression in osteosarcoma tissues (r = 0.83, P < 0.001). In addition, combined overexpression of CD10 and CD26 was observed in 52.59 % (61/116) of osteosarcoma tissues. CD10-high/CD26-high expression was significantly correlated with advanced clinical stage (P = 0.001), positive metastatic status (P = 0.001), shorter overall (P < 0.001) and disease-free (P < 0.001) survival in patients with osteosarcomas. Furthermore, multivariate survival analysis showed that clinical stage, metastatic status, CD10 expression, CD26 expression and combined expression of CD10/CD26 were all independent prognostic factors for predicting both overall and disease-free survival of osteosarcoma patients. Interestingly, combined expression of CD10/CD26 had a better prognostic value than other features. This retrospective study offer the convincing evidence for the first time that the overexpression of CD10 or CD26 may be an important feature of human osteosarcomas, and the combined expression of CD10/CD26 may be an efficient prognostic indicator for this disease.
中性内肽酶（NEP/CD10）和二肽基肽酶 IV（DPP IV/CD26）都是广泛存在的糖肽酶，在肿瘤的发病机制和发展中起着重要作用。本研究旨在探讨 CD10 和 CD26 在骨肉瘤患者中的表达模式及其预后意义。采用免疫组织化学法检测 116 对骨肉瘤及同一标本相应非癌骨组织中 CD10 和 CD26 的表达。计算骨肉瘤组织中 CD10 和 CD26 表达水平之间的斯皮尔曼相关性。随后评估 CD10 和 CD26 表达与骨肉瘤临床病理特征及预后的关系。骨肉瘤组织中 CD10 表达和 CD26 表达均明显高于相应非癌骨组织（均 P<0.001）。骨肉瘤组织中分别有 68.10%（79/116）和 70.69%（82/116）过度表达 CD10 和 CD26。骨肉瘤组织中 CD10 表达与 CD26 表达呈显著正相关（r=0.83，P<0.001）。此外，在 52.59%（61/116）的骨肉瘤组织中观察到 CD10 和 CD26 的联合过表达。CD10-高/CD26-高表达与晚期临床分期（P=0.001）、阳性转移状态（P=0.001）、骨肉瘤患者总生存期（P<0.001）和无病生存期（P<0.001）较短显著相关。此外，多变量生存分析表明，临床分期、转移状态、CD10 表达、CD26 表达和 CD10/CD26 的联合表达均是骨肉瘤患者总生存期和无病生存期的独立预后因素。有趣的是，CD10/CD26 的联合表达比其他特征具有更好的预后价值。这项回顾性研究首次提供了令人信服的证据，表明 CD10 或 CD26 的过度表达可能是人类骨肉瘤的一个重要特征，而 CD10/CD26 的联合表达可能是该疾病有效的预后指标。
